Status

Opening soon clinical trials

Studies whose latest retrieved public registry status is Opening soon.

671active studies

0recruiting now

57countries represented

218largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Opening soonPhase 3

Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk

Cardiometabolic Syndrome, Obesity and Cardiovascular RiskCondition

Bupropion 150 mg, Lyophilized powder from edible mushroomsTreatment

Sweden3 locations

Uppsala UniversitySponsor

Updated 2026-09-08 · NCT07806279See eligibility →

Opening soonPhase 1

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4329090, PlaceboTreatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808073See eligibility →

Opening soonPhase 1

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, Combined oral contraceptiveTreatment

United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808060See eligibility →

Opening soonPhase 2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Insulin Resistance, ObesityCondition

Alpha-lipoic acid, MirabegronTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-08 · NCT05713799See eligibility →

Opening soonNot applicable

Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

Obesity, DiabetesCondition

Intervention not listedTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-08 · NCT07388537See eligibility →

Opening soonNot applicable

A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity

ObesityCondition

Weight loss intervention, No Weight loss interventionTreatment

United States1 locations

National Institute of Environmental Health Sciences (NIEHS)Sponsor

Updated 2026-09-08 · NCT07437976See eligibility →

Opening soonPhase 1

A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)Condition

HRS-4729Treatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-09-08 · NCT07807059See eligibility →

Opening soonNot applicable

Comparing Two Low-Carbohydrate Diets With a Standard Diet in Type 2 Diabetes

Diabete Mellitus, Obesity & OverweightCondition

High-Protein Low-Carbohydrate Diet, High-Fat Low-Carbohydrate DietTreatment

Locations pending0 locations

National Nutrition and Food Technology InstituteSponsor

Updated 2026-09-08 · NCT07801378See eligibility →

Opening soonNot applicable

Family Grocery Study R01

Obesity, Diet, HealthyCondition

Recipes, Pre-filled cartsTreatment

Locations pending0 locations

State University of New York at BuffaloSponsor

Updated 2026-09-08 · NCT07806721See eligibility →

Opening soonPhase 3

UBT251 Injection Phase Ⅲ Study (OSA-PAP)

Obstructive Sleep Apnea, ObesityCondition

UBT251, UBT251Treatment

Locations pending0 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-09-08 · NCT07806851See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 3

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

ObesityCondition

Berobenatide, PlaceboTreatment

Japan12 locations

PfizerSponsor

Updated 2026-09-04 · NCT07794761See eligibility →

Opening soonPhase 3

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

ObesityCondition

Berobenatide, PlaceboTreatment

Japan11 locations

PfizerSponsor

Updated 2026-09-04 · NCT07794774See eligibility →

Opening soonNot applicable

Impact of Lifestyle on Health Maintenance: A Randomized Controlled Trial

Metabolic Syndrome, Inactivity/Low Levels of ExerciseCondition

Intervention of physical activity, Mediterranean Diet EducationTreatment

Croatia1 locations

University of ZadarSponsor

Updated 2026-09-04 · NCT07314957See eligibility →

Opening soonNot applicable

Efficacy of Mazdutide on Fatty Pancreas

Fatty Pancreas, OverweightCondition

mazdutide, Placebo matching mazdutideTreatment

China1 locations

Tongji HospitalSponsor

Updated 2026-09-04 · NCT07803705See eligibility →

Opening soonPhase 1

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Diabetes Mellitus, Type 1, OverweightCondition

Tirzepatide, AcetaminophenTreatment

United States1 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT07803744See eligibility →

Opening soonPhase 2

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

Overweight or ObesityCondition

SYH2069 Injection, SYH2069 Injection PlaceboTreatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-09-04 · NCT07803991See eligibility →

Opening soonNot applicable

Network-Based Support to Help Community Coalition Members Choose and Use Strategies to Improve Child Health

Childhood Obesity, Evidence-Based PracticeCondition

Catalyzing Communities, FICAS Implementation InterventionTreatment

United States1 locations

University of PittsburghSponsor

Updated 2026-09-04 · NCT07804550See eligibility →

Opening soonPhase 3

Vibegron for ENergy Thinking and Resilience in Aging

ObesityCondition

Vibegron, PlaceboTreatment

United States1 locations

Wake Forest University Health SciencesSponsor

Updated 2026-09-03 · NCT06987383See eligibility →

Opening soonNot applicable

Digitally Enhanced Cognitive-Behavioral Therapy

Depression in Adolescence, Obesity & OverweightCondition

Cognitive-behavioral therapy (CBT), Digital appTreatment

United States1 locations

Colorado State UniversitySponsor

Updated 2026-09-03 · NCT07569991See eligibility →

Opening soonPhase 1

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity

Overweight, ObesityCondition

BI 3034701, PlaceboTreatment

Germany1 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754474See eligibility →

Opening soonPhase 1

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

End Stage Renal Disease, Renal ImpairmentCondition

RibupatideTreatment

United States1 locations

KaileraSponsor

Updated 2026-09-03 · NCT07793929See eligibility →

Opening soonPhase 1

An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants

Overweight, ObesityCondition

IBI3042, PlaceboTreatment

China1 locations

Hongwei JiangSponsor

Updated 2026-09-03 · NCT07802899See eligibility →

Opening soonNot applicable

Leveraging Interactive Digital Technology to Increase Access to Family-Based Behavioral Treatment for Childhood Obesity

Childhood ObesityCondition

FBT 2.0, Information-and-referralTreatment

United States1 locations

3-C Institute for Social DevelopmentSponsor

Updated 2026-09-02 · NCT06728800See eligibility →

Opening soonNot applicable

Study Evaluating the Safety and Feasibility of Endoscopic Duodenal Injections of Autologous Mesenchymal Stem Cells

Diabete Type 2, Insulin Resistant Diabetes (Mellitus)Condition

endoscopic duodenal injection of ADMSCsTreatment

Locations pending0 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-02 · NCT07344324See eligibility →

Opening soonNot applicable

Vitis Intervention Trial in Substrate Metabolism

Obesity & Overweight, Healthy AdultCondition

Freeze-Dried Whole Grape Powder, PlaceboTreatment

Locations pending0 locations

University of Alabama at BirminghamSponsor

Updated 2026-09-02 · NCT07800988See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

Opening soonNot applicable

A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists

Obesity & Overweight, GLP - 1Condition

Ubiquinol 100 MG Oral Capsule, PlaceboTreatment

United Kingdom1 locations

StudySetGoSponsor

Updated 2026-09-01 · NCT07789106See eligibility →

Opening soonNot applicable

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

Obesity, Type 2 DiabetesCondition

Almond DietTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-09-01 · NCT07796204See eligibility →

Opening soonPhase 2

A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

T2DM (Type 2 Diabetes Mellitus)Condition

SYH2069 Injection (group 1), SYH2069 Injection (group 2)Treatment

China1 locations

CSPC Ouyi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07796477See eligibility →

Opening soonPhase 2, Phase 3

Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes

Gestational Diabetes Mellitus (GDM), Metabolic SyndromeCondition

Semaglutide (Wegovy) weekly injectionTreatment

United States1 locations

University of Massachusetts, WorcesterSponsor

Updated 2026-09-01 · NCT07797036See eligibility →

Opening soonNot applicable

Chia Seed Impact on Postprandial Glycemia and Appetite in Overweight Adults

Overweight Adults, Postprandial GlycemiaCondition

Chia Seed (Salvia hispanica L.) BeverageTreatment

Pakistan1 locations

University of Veterinary and Animal Sciences, Lahore - PakistanSponsor

Updated 2026-09-01 · NCT07797049See eligibility →

Opening soonNot applicable

Pilot Study of Endoscopic Sleeve Gastroplasty for Obese Patients With Heart Failure and Preserved Ejection Fraction

Obesity (BMI>30), Heart Failure With Preserved Ejection Fraction (HFPEF)Condition

Endoscopic sleeve gastroplasty (ESG)Treatment

United States1 locations

Cedars-Sinai Medical CenterSponsor

Updated 2026-09-01 · NCT07798219See eligibility →

Opening soonNot applicable

Characterisation of MNEsic Involvement in Patients With Obesity.

Obesity (Disorder)Condition

RMI and QuestionnairesTreatment

Locations pending0 locations

University Hospital, BordeauxSponsor

Updated 2026-09-01 · NCT07796932See eligibility →

Opening soonNot applicable

Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis

Cirrhosis, Portal HypertensionCondition

Mazdutide injectionTreatment

Locations pending0 locations

The Second Affiliated Hospital of Chongqing Medical UniversitySponsor

Updated 2026-09-01 · NCT07797101See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonNot applicable

A Trial to Examine the Effects of a Weight Loss Program Emphasizing Protein, Dietary Fiber, and Exercise (30-30-30 Plan)

Overweight , ObesityCondition

30-30-30 PFE Intervention, StandardTreatment

United States3 locations

Midwest Center for Metabolic and Cardiovascular ResearchSponsor

Updated 2026-08-31 · NCT07789769See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.

Obesity / OverweightCondition

TQF6422 Injection, TQF6422 PlaceboTreatment

China1 locations

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07794111See eligibility →

Opening soonPhase 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea (OSA) and ObesityCondition

HDM1005, PlaceboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07794397See eligibility →

Opening soonPhase 4

PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Diabete Type 2, Pharmacogenomic Drug InteractionCondition

OrforglipronTreatment

Locations pending0 locations

Massachusetts General HospitalSponsor

Updated 2026-08-31 · NCT07739537See eligibility →

Opening soonNot applicable

The Effectiveness of Respiratory Muscle Training and Exercise in Obese Adolescents

Obesity (Disorder)Condition

Respiratory Muscle Training, ExerciseTreatment

Locations pending0 locations

Medipol UniversitySponsor

Updated 2026-08-31 · NCT07787546See eligibility →

Opening soonPhase 4

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

Obesity & Overweight, Coronary Heart DiseaseCondition

Mazdutide, PlaceboTreatment

China1 locations

China National Center for Cardiovascular DiseasesSponsor

Updated 2026-08-28 · NCT07657676See eligibility →

Opening soonPhase 1

A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

HealthyCondition

MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2)Treatment

United States1 locations

Merck Sharp & Dohme LLCSponsor

Updated 2026-08-28 · NCT07748351See eligibility →

Opening soonPhase 2

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

Type 2 Diabetes Mellitus (T2DM), SarcopeniaCondition

Calcium-HMB Plus Vitamin D3, Matching placeboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-08-28 · NCT07760948See eligibility →

Opening soonNot applicable

Weight and Metabolic Management Study

Overweight, ObesityCondition

elénzia CONTROL®, PlaceboTreatment

United Kingdom1 locations

ElenziaSponsor

Updated 2026-08-28 · NCT07789223See eligibility →

Opening soonNot applicable

ENLIGHT Trial: ESG With Fundal Mucosal Ablation

Obesity, Obesity (Body Mass Index >30 kg/m2)Condition

Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal AblationTreatment

United States1 locations

West Virginia UniversitySponsor

Updated 2026-08-28 · NCT07792226See eligibility →

Opening soonPhase 1

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

Overweight, Healthy ParticipantsCondition

Orforglipron, Matching PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-08-28 · NCT07793019See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonNot applicable

PLAY2CONTROL Study

Type 2 Diabetes, Obesity & OverweightCondition

Nex Playground Activity ProgramTreatment

United States1 locations

University of MiamiSponsor

Updated 2026-08-27 · NCT07556679See eligibility →

Opening soonNot applicable

Long-term Effects of Avocado Consumption on Health in Pre-diabetic Individuals

Prediabetes, Brain Insulin SensitivityCondition

AvocadosTreatment

Netherlands1 locations

Maastricht University Medical CenterSponsor

Updated 2026-08-27 · NCT07752225See eligibility →

Opening soonPhase 2

Obesity Treatment Using Phentermine-Topiramate ER to Improve Metabolic Health in Adolescents Surviving Leukemia and Lymphoma

Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in RemissionCondition

Phentermine/Topiramate ER, Health Behavior and Lifestyle CounselingTreatment

United States1 locations

St. Jude Children's Research HospitalSponsor

Updated 2026-08-27 · NCT07790913See eligibility →

Opening soonNot applicable

Does Estrogen Blunt the Effects of Exercise Training on Glycemic Control

To Determine Whether Estrogen Influences the Effects of Training on Glycemic Control and Insulin SensitivityCondition

EXERCISE TRAINING WITH OR WITHOUT MEDICATIONTreatment

Canada1 locations

University of WaterlooSponsor

Updated 2026-08-27 · NCT07791394See eligibility →

Opening soonPhase 2

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaCondition

Medical Device Usage and Evaluation, TirzepatideTreatment

United States3 locations

National Cancer Institute (NCI)Sponsor

Updated 2026-08-26 · NCT07349641See eligibility →

Opening soonPhase 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea (OSA) and ObesityCondition

HDM1005, PlaceboTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-26 · NCT07787260See eligibility →

Opening soonNot applicable

EMS vs. Resistance Training in Overweight Women

Obesity & OverweightCondition

Resistance Training, Electrical Muscle StimulationTreatment

Iran1 locations

Birjand University of Medical SciencesSponsor

Updated 2026-08-26 · NCT07787286See eligibility →

Opening soonNot applicable

Digital Resistance Training for Midlife Women Using GLP-1

Women's Health, Obesity & OverweightCondition

PLAN-RT 1.0Treatment

United States1 locations

Louisiana State University and A&M CollegeSponsor

Updated 2026-08-26 · NCT07787533See eligibility →

Opening soonNot applicable

GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

Heart Failure With Preserved Ejection Fraction, ObesityCondition

GLP-1 / GIP receptor agonistTreatment

Poland1 locations

Miedziowe Centrum Zdrowia SASponsor

Updated 2026-08-26 · NCT07787936See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related statuses

Recruiting now1,541 Active, not recruiting664 Invitation only133

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.